Eliot A. Brinton
About
Eliot A. Brinton is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine.
According to data from OpenAlex, Eliot A. Brinton has authored 153 papers receiving a total of 12.1k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Surgery, 88 papers in Endocrinology, Diabetes and Metabolism and 33 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Eliot A. Brinton's work include Lipoproteins and Cardiovascular Health (76 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (55 papers) and Fatty Acid Research and Health (22 papers). Eliot A. Brinton is often cited by papers focused on Lipoproteins and Cardiovascular Health (76 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (55 papers) and Fatty Acid Research and Health (22 papers). Eliot A. Brinton collaborates with scholars based in United States, Canada and France. Eliot A. Brinton's co-authors include Terry A. Jacobson, Jan L. Breslow, Michael Miller, S Eisenberg, Christie M. Ballantyne, Philippe Gabríel Steg, Deepak L. Bhatt, Jean‐Claude Tardif, Ralph T. Doyle and Rebecca A. Juliano and has published in prestigious journals such as Science, New England Journal of Medicine and JAMA.
In The Last Decade
Eliot A. Brinton
148 papers receiving 11.8k citations
Hit Papers
Peers
Eliot A. Brinton
Samia Mora United States
Paul N. Hopkins United States
Mark J. Caulfield United Kingdom
Eric J.G. Sijbrands Netherlands
Sander J. Robins United States
M. John Chapman France
Jiří Fröhlich Canada
Jean MacFadyen United States
H. A. W. Neil United Kingdom
Hiroshi Mabuchi Japan
Citations per year, relative to Eliot A. Brinton Eliot A. Brinton (= 1×)
peers
Samia Mora
Countries citing papers authored by Eliot A. Brinton
Since
Specialization
Citations
This map shows the geographic impact of Eliot A. Brinton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eliot A. Brinton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eliot A. Brinton more than expected).
Fields of papers citing papers by Eliot A. Brinton
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Eliot A. Brinton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eliot A. Brinton. The network helps show where Eliot A. Brinton may publish in the future.
Co-authorship network of co-authors of Eliot A. Brinton
This figure shows the co-authorship network connecting the top 25 collaborators of Eliot A. Brinton. A scholar is included among the top collaborators of Eliot A. Brinton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eliot A. Brinton. Eliot A. Brinton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Brinton, Eliot A., Frederick J. Raal, Jean Bergeron, et al.. (2025). Evinacumab in patients aged 5–17 years with homozygous familial hypercholesterolemia. Atherosclerosis. 413. 120627–120627.
2.
Dingman, Robert, Jeanne Mendell, Katy C. Norman, et al.. (2025). Comparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia. CPT Pharmacometrics & Systems Pharmacology. 14(11). 1835–1847.
3.
Aggarwal, Rahul, Deepak L. Bhatt, Philippe Gabríel Steg, et al.. (2025). Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized Trial. Journal of the American Heart Association. 14(5). e038656–e038656.
4.
Bhatt, Deepak L., Robert P. Giugliano, Philippe Gabríel Steg, et al.. (2025). Benefit of icosapent ethyl across types and sizes of myocardial infarction in REDUCE-IT. European Journal of Preventive Cardiology.
5.
Myerson, Merle, Rodis Paparodis, Robert Block, et al.. (2024). Polycystic ovary syndrome: A review of diagnosis and management, with special focus on atherosclerotic cardiovascular disease prevention. Journal of clinical lipidology. 18(4). e488–e500.
6.
Wiegman, Albert, Susanne Greber‐Platzer, Shazia Ali, et al.. (2023). Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia. Circulation. 149(5). 343–353.
7.
Olshansky, Brian, Deepak L. Bhatt, Michael Miller, et al.. (2023). Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT. Journal of the American Heart Association. 12(5). e026756–e026756.
8.
Ridker, Paul M., Nader Rifai, Jean MacFadyen, et al.. (2022). Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. Circulation. 146(5). 372–379.
9.
Kling, Juliana M., N. Maritza Dowling, Heather A. Bimonte‐Nelson, et al.. (2022). Associations between pituitary-ovarian hormones and cognition in recently menopausal women independent of type of hormone therapy. Maturitas. 167. 113–122.
10.
Sampson, Maureen, Rami A. Ballout, Daniel Soffer, et al.. (2021). A new phenotypic classification system for dyslipidemias based on the standard lipid panel. Lipids in Health and Disease. 20(1). 170–170.
11.
Wang, Xiaowen, Deepak L. Bhatt, Michael Miller, et al.. (2021). ICOSAPENT ETHYL REDUCES ISCHEMIC EVENTS IN PATIENTS WITH HIGH TRIGLYCERIDES AND LOW HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS: REDUCE-IT HIGH TG/LOW HDL-C ANALYSES. Journal of the American College of Cardiology. 77(18). 155–155.
12.
Majithia, Arjun, Deepak L. Bhatt, Allon N. Friedman, et al.. (2020). Benefits of Icosapent Ethyl Across a Range of Baseline Renal Function in Patients with Established Cardiovascular Disease or Diabetes: Results of REDUCE-IT RENAL. Journal of the American Society of Nephrology. 31(10S). 21–21.
13.
Peterson, Benjamin E., Deepak L. Bhatt, Philippe Gabríel Steg, et al.. (2020). TCT CONNECT-3 Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI. Journal of the American College of Cardiology. 76(17). B1–B2.
14.
Weintraub, William, Deepak L. Bhatt, Zugui Zhang, et al.. (2020). COST-EFFECTIVENESS OF ICOSAPENT ETHYL IN US REDUCE-IT PATIENTS. Journal of the American College of Cardiology. 75(11). 1914–1914.
15.
Brinton, Eliot A., Paul N. Hopkins, Robert A. Hegele, et al.. (2017). The association between hypercholesterolemia and sitosterolemia, and report of a sitosterolemia kindred. Journal of clinical lipidology. 12(1). 152–161.
16.
Brinton, Eliot A. & R. Preston Mason. (2017). Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA). Lipids in Health and Disease. 16(1). 23–23.
17.
Martin, Seth S., Michael J. Blaha, Mohamed B. Elshazly, et al.. (2013). Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications. Journal of the American College of Cardiology. 62(8). 732–739.
18.
Gotto, Antonio M., Christopher P. Cannon, Sukrut Shah, et al.. (2011). Abstract 15035: Effects on Lipids and Safety Following Cessation of Treatment with Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. Circulation. 124(10). 3673–81.
19.
Constantine, Ryan, et al.. (2007). Vascular Endothelial Growth Factor (VEGF) Polymorphisms and Their Association With Age-Related Macular Degeneration. Investigative Ophthalmology & Visual Science. 48(13). 2097–2097.
20.
Hopkins, Paul N., Lily Wu, Steven C. Hunt, & Eliot A. Brinton. (2005). Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. Journal of the American College of Cardiology. 45(7). 1003–1012.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Samia Mora Breakdown of academic impact, for papers by Paul N. Hopkins Breakdown of academic impact, for papers by Mark J. Caulfield Breakdown of academic impact, for papers by Eric J.G. Sijbrands Breakdown of academic impact, for papers by Sander J. Robins Breakdown of academic impact, for papers by M. John Chapman Breakdown of academic impact, for papers by Jiří Fröhlich Breakdown of academic impact, for papers by Jean MacFadyen Breakdown of academic impact, for papers by H. A. W. Neil Breakdown of academic impact, for papers by Hiroshi Mabuchi